Enhancing the Extraordinary
Our Story
Founder's Vision
Lyell Founder and Board Chair Rick Klausner, M.D., shares his vision for conquering oncology’s unfinished business.
Our Science
Technology designed to generate CAR T cells that deliver more durable outcomes for patients with cancer.
Our Pipeline
Our pipeline targets hematologic malignancies and solid tumors with significant unmet medical need.
Dedicated to Patients
An unwavering focus on science guides our mission to deliver transformative CAR T-cell therapies for patients with solid tumors and hematologic malignancies.
Learn MoreLatest News
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif.,
View All NewsJoin Our Team
At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients.
Join our team of ambitious Lyellites who are committed to defeating cancer through innovation.
See Open Positions